Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Pharma Inc.

www.astellas.com

Latest From Astellas Pharma Inc.

Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas

Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.

Business Strategies Clinical Trials

Oncology, Orphans Dominate Japan Fiscal 2018 Approvals

Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.

Japan Approvals

ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going

The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.

Financing Cancer

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register